Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05001477 · ClinicalTrials.gov registry record
Customized TULSA-PRO Ablation Registry
A clinical trial of Prostate Cancer and Prostate Adenocarcinoma, sponsored by Profound Medical.
- Recruiting
- Registry status
- 1,000
- Enrollment target
- 5
- Study locations
NCT05001477: Recruiting study of Prostate Cancer and Prostate Adenocarcinoma, sponsored by Profound Medical.
NCT05001477 is a study of Prostate Cancer and Prostate Adenocarcinoma that is actively recruiting participants, run by Profound Medical. The registered enrollment target is 1,000 participants, above the 607-participant average among 735 other Prostate Cancer trials with a reported enrollment target (65% higher). The trial reports 5 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05001477, a study of Prostate Cancer and Prostate Adenocarcinoma, is actively recruiting participants, sponsored by Profound Medical.
- RECRUITING
- Registry status
- 1,000 participants
- Enrollment target
- 5
- Study locations
Study Summary
This patient registry will capture data from patients who have been or who are undergoing the transurethral ultrasound ablation (TULSA) procedure as part of their routine clinical care. The registry will shed light on real-world outcomes of safety and efficacy of the procedure and understand how a patient's quality of life is affected throughout their follow-up and lifetime.
Primary Outcome
estimating the rate of complications (Clavien-Dindo grades III - IV) attributable to the TULSA Procedure
Conditions Studied
Interventions
- DEVICE TULSA Procedure
Study Locations (5)
Texas
- University of Texas Southwestern Medical Center - Dallas
- Urology Place - San Antonio
California
- RadNet's Liberty Pacific West Hills Facility - West Hills
Florida
- Mayo Clinic Jacksonville - Jacksonville
Pennsylvania
- Wellspan Health - York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,000 participants |
| Start Date | 2021-10-27 |
| Est. Completion | 2061-10 |
What NCT05001477 shows while recruiting
NCT05001477 is an observational study that tracks outcomes without assigning an intervention. Its 1,000 participants enrollment target places it among the larger protocols in the corpus, above the 607-participant average among 735 other Prostate Cancer trials with a reported enrollment target (65% higher).
The record links to 3 conditions, with Prostate Cancer appearing as the primary indexed condition, and to 1 intervention - of which TULSA Procedure is the first listed.
NCT05001477 lists 5 locations in 4 states (Texas, California, Florida).
Frequently Asked Questions
What is clinical trial NCT05001477 about?
NCT05001477 is a clinical study titled "Customized TULSA-PRO Ablation Registry". This patient registry will capture data from patients who have been or who are undergoing the transurethral ultrasound ablation (TULSA) procedure as part of their routine clinical care. The registry will shed light on real-world outcomes of safety and efficacy of the procedure and understand how a p...
What is the current status of trial NCT05001477?
This trial is currently recruiting. The enrollment target is 1,000 participants. The study started on 2021-10-27. Estimated completion is 2061-10.
What conditions does trial NCT05001477 study?
This clinical trial studies the following conditions: Prostate Cancer, Prostate Adenocarcinoma, Benign Prostatic Hyperplasia.
What interventions are being tested in trial NCT05001477?
The interventions under investigation include: TULSA Procedure (DEVICE).
Who is sponsoring clinical trial NCT05001477?
This trial is sponsored by Profound Medical, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05001477 being conducted?
This trial has 5 study locations across California, Florida, Pennsylvania, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05001477's enrollment target sits among peer trials
1,000 59th of 735 higher than 669 of 735 other Prostate Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Prostate Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
Performance of Inherited Risk Assessment for Predicting Prostate Cancer From Prostate Biopsy
RECRUITING
-
Trial of Neoadjuvant Enoblituzumab vs SOC in Men With High-Risk Localized Prostate Cancer
RECRUITING · Phase 2
-
Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis
RECRUITING
-
Improving Health Literacy in African-American Prostate Cancer Patients
RECRUITING · NA
-
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00018044 · 1,000 participants
Study of Mycobacterial Infections
- NCT01036581 · 1,000 participants · NA
Advanced Functional and Structural MRI Techniques for Neuropharmacological Imaging
- NCT01192048 · 1,000 participants
Genetics of Congenital Heart Disease
- NCT01553214 · 1,000 participants · Phase 4
Improving White Blood Cell Collection From Healthy Donors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI